10 November 2014

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that Blue Diamond®™, Futura's own-brand of its novel CSD500 condom, has in its first month since launch rapidly achieved an estimated 15% share of the Netherlands online condom market by value.

Blue Diamond® was launched on 9 October 2014 as an online-only product by Bizzy Diamond BV, Futura's distribution partner for the Netherlands and Belgium. Since that time the product has attracted considerable local media coverage including a number of national TV programmes and radio station interviews and reviews.

Customer feedback from those that have used the product has been favourable. In addition, the conversion rate of customers visiting the Blue Diamond® website, www.bluediamondcondom.com, and then buying the product has been encouraging. We have also started to see repeat buying of Blue Diamond®.

The launch of Blue Diamond® has prompted considerable interest from other e-tailers wishing to sell the product and also from traditional retailers. Futura is currently reviewing this interest and expects to make Blue Diamond® available at further outlets for Dutch and Belgian customers.

Blue Diamond® is Futura's own-brand of its CSD500 condom, which contains Futura's erectogenic gel Zanifil®. CSD500 benefits from three marketing claims, which have been clinically proven and approved by EU regulatory authorities: the maintenance of a firmer erection, maximised penile size and a longer lasting sexual experience for women.

James Barder, Futura's Chief Executive, said: "We are delighted by the initial response to Blue Diamond® in the Netherlands and Belgium. It has quickly gained an estimated 15% of the online condom market in the Netherlands, reflecting the condom's novel qualities. We have been approached by a considerable number of e-tailers and retailers interested in stocking the product and it is our intention to widen local distribution as part of our strategy to drive awareness of the product and grow sales."

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to Editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com